127 related articles for article (PubMed ID: 38884175)
1. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Röth A; He G; Tong H; Lin Z; Wang X; Chai-Adisaksopha C; Lee JH; Brodsky A; Hantaweepant C; Dumagay TE; Demichelis-Gómez R; Rojnuckarin P; Sun J; Höglund M; Jang JH; Gaya A; Silva F; Obara N; Kelly RJ; Beveridge L; Buatois S; Chebon S; Gentile B; Lundberg P; Sreckovic S; Nishimura JI; Risitano A; Han B
Am J Hematol; 2024 Jun; ():. PubMed ID: 38884175
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
Liu H; Xia L; Weng J; Zhang F; He C; Gao S; Jia J; Chang AC; Lundberg P; Shi J; Sima CS; Sostelly A; Sreckovic S; Xiao Z; Zhang Z; Fu R
Am J Hematol; 2023 Sep; 98(9):1407-1414. PubMed ID: 37421604
[TBL] [Abstract][Full Text] [Related]
3. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Schrezenmeier H; Kulasekararaj A; Mitchell L; Sicre de Fontbrune F; Devos T; Okamoto S; Wells R; Rottinghaus ST; Liu P; Ortiz S; Lee JW; Socié G
Ther Adv Hematol; 2020; 11():2040620720966137. PubMed ID: 33178408
[TBL] [Abstract][Full Text] [Related]
4. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A; Ichikawa S; Ito Y; Kim JS; Nagy Z; Obara N; Panse J; Schrezenmeier H; Sica S; Soret J; Usuki K; Yoon SS; Balachandran N; Buri M; Lundberg P; Patel H; Shinomiya K; Sostelly A; Nishimura JI
Eur J Haematol; 2023 Aug; 111(2):300-310. PubMed ID: 37321625
[TBL] [Abstract][Full Text] [Related]
5. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
[TBL] [Abstract][Full Text] [Related]
6. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
8. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
9. Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Nishimura JI; Soubret A; Arase N; Buatois S; Hotta M; Charoin JE; Ito Y; Sreckovic S; Takamori H; Bucher C; Ueda Y; Hernández-Sánchez J; Gotanda K; Jordan G; Shinomiya K; Ramos J; Kim JS; Panse J; de Latour RP; Röth A; Morii E; Schrezenmeier H; Isaka Y; Sica S; Kanakura Y; Yoon SS; Kinoshita T; Paz-Priel I; Sostelly A
Clin Pharmacol Ther; 2023 Apr; 113(4):904-915. PubMed ID: 36660902
[TBL] [Abstract][Full Text] [Related]
10. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R
Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221
[TBL] [Abstract][Full Text] [Related]
11. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
12. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
15. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
16. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
18. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
[TBL] [Abstract][Full Text] [Related]
19. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
